Former pharmaceutical CEO Martin Shkreli will be allowed to travel to Washington for a House hearing on drug prices, which has been delayed a week because of the blizzard.
The House Oversight Committee will hold the hearing Feb. 4 after the original Tuesday date was postponed.
A federal judge ruled on Monday that Shkreli, the former CEO of Turing Pharmaceuticals, can travel to Washington for the hearing. Shkreli faces securities fraud charges and has said he couldn’t leave New York City to go to Washington due to the pending charges.
When Shkreli was Turing’s CEO, he infamously raised the price of a generic anti-parasite treatment by 5,000 percent in September. He resigned from Turing soon after being charged in December for unrelated securities fraud.
The witness list also includes Howard Schiller, the interim CEO of Valeant Pharmaceuticals. That company also was criticized for raising the prices of several heart drugs by more than 200 percent.
Janet Woodcock, the head of the Food and Drug Administration’s Center for Drug Evaluation, also is scheduled to appear. Several lawmakers have criticized the FDA for approving generic drugs too slowly, which they say has stifled competition and led to higher prices.
